Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P900056/S228

ROTAPRO Rotational Atherectomy System

Boston Scientific Corp · Decision date Oct 20, 2026

MEDTECHLEDGER EXPLANATIONP900056/S228

What did the FDA decide?

The FDA record P900056/S228 shows an OK30 decision dated 2026-10-20 for a 30-Day Notice supplement to PMA P900056, submitted by Boston Scientific Corp for the ROTAPRO Rotational Atherectomy System, a coronary atherectomy catheter under product code MCX. The stated supplement reason is a process change involving the manufacturer, sterilizer, packager or supplier.

The source statement describes updates to the PCBA adhesive inspection process and the introduction of new adhesive dispensers for the device. Because this is a supplement to an existing PMA rather than a new approval of the whole system, the notice concerns manufacturing process details only, and the record does not describe the prior inspection method, dispenser specifications, validation data, or any safety or effectiveness findings.

Specific information absent from the supplied fields includes which manufacturing site is affected and what evidence supported the change.

FDA approval order statement

updates to the PCBA adhesive inspection process and introduction of new adhesive dispensers for the ROTAPRO Rotational Atherectomy System
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 20, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P900056/S228
Regulatory pathway
PMA supplement
Product code
MCX
Decision code
OK30
Decision date
Oct 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: CATHETER, CORONARY, ATHERECTOMY.

Product code
MCX
FDA device class
3

For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P900056/S228 received

    Application receipt date recorded by FDA.

  2. P900056/S228 · FDA decision

    30-Day Notice

  3. P900056/S226 · Related supplement

    ROTAPRO Rotational Atherectomy Systems

  4. P900056/S229 · Related supplement

    ROTAPRO Rotational Atherectomy System

Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P900056

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalMay 28, 1993FDA
Boston Scientific CorpPMA supplementOct 21, 2026FDA
Boston Scientific CorpPMA supplementOct 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
Two Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records